• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Protective Effects of Intravenous Magnesium Sulfate in Stroke Patients Receiving Amiodarone: A Randomized Controlled Trial
Adv Exp Med Biol. 2021;1308:579-588. doi: 10.1007/978-3-030-64872-5_28.ABSTRACTAnti-arrhythmic agents, like amiodarone, interfere at different stages of the ischemic stroke. However, amiodarone was accompanied with immunological pulmonary complications and adverse neurological effects. We hypothesize that magnesium sulfate in combination with amiodarone holds promise for stroke treatment. Thirty-six patients with confirmed diagnosis of ischemic stroke and atrial fibrillation who received bolus amiodarone were randomly assigned to magnesium sulfate every 24 h or similar volume of normal saline (as placebo) for 5 days. Vario...
Source: Advances in Experimental Medicine and Biology - April 16, 2021 Category: Research Authors: Yunes Panahi Mojtaba Mojtahedzadeh Atabak Najafi Mohammadreza Gheini Mohammad Abdollahi Mohammad Sharifzadeh Arezoo Ahmadi Shiva Ganjali Seyyed Mahdi Rajaee George E Barreto Amirhossein Sahebkar Source Type: research

What Are Some Risk Factors for Cerebral Palsy?
Discussion The term, cerebral palsy, or CP has gone through many iterations with the first description in 1861 by W.J. Little who described it as “The condition of spastic rigidity of the limbs of newborn children.” The most recent definition is from Rosenbaun et al. in 2007 which states it is “a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, perception, cog...
Source: PediatricEducation.org - March 9, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Orally Administered Crocin Protects Against Cerebral Ischemia/Reperfusion Injury Through the Metabolic Transformation of Crocetin by Gut Microbiota
Conclusion Collectively, pharmacokinetic and pharmacodynamic association studies provide evidence that the gut microbiota plays a vital role in the fate of crocin and crocetin in the gastrointestinal tract. In addition, the cross-interaction between gut microbiota and crocin might mediate the activation of the cerebral-protective effect of orally administered crocin. Ethics Statement This study was carried out in accordance with the recommendations of ‘Institutional Animal Research Committee guidelines, Animal Ethics Committee of China Pharmaceutical University.’ The protocol was approved by the ‘An...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Glutamate Transport and Preterm Brain Injury
Silvia Pregnolato1*, Elavazhagan Chakkarapani1, Anthony R. Isles2 and Karen Luyt1 1Department of Neonatal Neurology, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom 2Behavioural Genetics Group, MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, United Kingdom Preterm birth complications are the leading cause of child death worldwide and a top global health priority. Among the survivors, the risk of life-long disabilities is high, including cerebral palsy and impairment of movement, cognition, and beh...
Source: Frontiers in Physiology - April 23, 2019 Category: Physiology Source Type: research

A Pregnancy Complication to Look out for even after Pregnancy
​BY GREGORY TAYLOR, DO, & SHERIF G. EL-ALAYLI, DOA 30-year-old G5P3 presented to the ED with bilateral lower-extremity edema and headache for three days. She presented one week after an uncomplicated full-term vaginal delivery with an unremarkable pregnancy course and no prior requirement for antihypertensive therapy. The headache was described as achy to sharp, with associated photophobia. She also noted occasional vaginal spotting, which was common a few weeks after delivery. She denied any chest pain, shortness of breath, nausea or vomiting, abdominal pain, or any other symptoms. She admitted to occasional mild cr...
Source: The Case Files - August 28, 2018 Category: Emergency Medicine Tags: Blog Posts Source Type: research

A meta-analysis of pharmacological neuroprotection in noncardiac surgery: focus on statins, lidocaine, ketamine, and magnesium sulfate.
CONCLUSIONS: The available clinical data are still scarce. Our analyses indicate no protective effects by statins against perioperative stroke but some favorable trends toward delayed stroke. Further randomized trials are needed to unequivocally assess the neuroprotective potential of current pharmacological agents in non-cardiac surgery. PMID: 29630129 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - April 10, 2018 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Paramedic Initiation of Neuroprotective Agent Infusions Clinical Sciences
Conclusions—Paramedic infusion initiation using gravity-controlled tubing permits rapid achievement of target serum levels of potential neuroprotective agents. The absence of association of clinical outcomes with achieved magnesium levels provides further evidence that magnesium is not biologically neuroprotective in acute stroke.
Source: Stroke - June 26, 2017 Category: Neurology Authors: Kristina Shkirkova, Sidney Starkman, Nerses Sanossian, Marc Eckstein, Samuel Stratton, Frank Pratt, Robin Conwit, Scott Hamilton, Latisha Sharma, David Liebeskind, Lucas Restrepo, Miguel Valdes-Sueiras, Jeffrey L. Saver Tags: Cerebrovascular Disease/Stroke, Neuroprotectants Original Contributions Source Type: research

Modified Rankin Scale Disability Status at Day 4 Poststroke is an Informative Predictor of Final Day 90 Outcome (P6.271)
Conclusions:In acute stroke patients, the 4d modified Rankin global disability assessment is highly informative regarding final 3 month mRS disability outcome, alone, and even more strongly in combination with baseline prognostic variables. The 4d mRS is a useful measure for imputing final patient disability outcome in clinical trials and quality improvement programs.Disclosure: Dr. Asanad has nothing to disclose. Dr. Starkman has received research support from the National Institute of Health, Stryker, Biogen IDEC, Neuravi, Genentech, Covidien, and Astra-Zeneca. Dr. Hamilton has nothing to disclose. Dr. Conwit has nothing...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Asanad, S., Starkman, S., Hamilton, S., Conwit, R., Sanossian, N., Saver, J. Tags: Cerebrovascular Disease Health Services Research Source Type: research

Neuroprotective strategies and the underlying molecular basis of cerebrovascular stroke.
Abstract Stroke is a leading cause of disability in the US. Although there has been significant progress in the area of medical and surgical thrombolytic technologies, neuroprotective agents to prevent secondary cerebral injury and to minimize disability remain limited. Only limited success has been reported in preclinical and clinical trials evaluating a variety of compounds. In this review, the authors discuss the most up-to-date information regarding the underlying molecular biology of stroke as well as strategies that aim to mitigate this complex signaling cascade. Results of historical research trials involvi...
Source: Neurosurgical Focus - April 1, 2017 Category: Neurosurgery Authors: Karsy M, Brock A, Guan J, Taussky P, Kalani MY, Park MS Tags: Neurosurg Focus Source Type: research

Pages: 1  2